Renal microcirculation and calcium channel subtypes

Current Hypertension Reviews

Volumn 9, Issue 3, 2013, Pages 182-186

  Homma, Koichiro ^a   Hayashi, Koichi ^a   Yamaguchi, Shintaro ^a   Fujishima, Seitaro ^a   Hori, Shingo ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Afferent arterioles; Efferent arterioles; Glomerular pressure; Renal injury

Indexed keywords

ALDOSTERONE; AMLODIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL T TYPE; CILNIDIPINE; EFONIDIPINE; MIBEFRADIL; CALCIUM CHANNEL BLOCKING AGENT;

ADRENAL GLAND; ALDOSTERONE RELEASE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EFFERENT NERVE; GLOMERULUS CAPILLARY; HISTOLOGY; HUMAN; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY INNERVATION; MICROCIRCULATION; NERVE ENDING; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEINURIA; RENAL MICROCIRCULATION; RENIN RELEASE; SENSORY NERVE; SYMPATHETIC NERVE; SYMPATHETIC TONE; ANIMAL; ARTERIOLE; BLOOD; CLASSIFICATION; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULE; VASCULARIZATION;

ALDOSTERONE; ANIMALS; ARTERIOLES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; MICROCIRCULATION;

EID: 84900805797     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402110666140131160617     Document Type: Article

References (29)

1. Heller J, Horacek V. The effect of two different calcium antagonists on the glomerular haemodynamics in dogs. Eur J Physiol 1990; 415: 751-755.
2. Loutzenhiser R, Epstein M, Fischetti F, Horton C. Effects of amlodipine on renal hemodynamics. Am J Cardiol 1989; 64: 1221-1271.
3. Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am J Physiol 1986; 251: F57-F65.
4. Kimura K, Nagai R, Sasaki T, et al. Diversity and variability of smooth muscle phenotypes of renal arterioles as revealed by myosine isoform expression. Kidney Int 1995; 48: 372-382.
5. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
6. Hansen PB, Jensen BL, Andreasen D, Skøtt O. Differential expression of T-and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
7. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-36.
8. Honda M, Hayashi K, Matsuda H, et al. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001; 19: 2031-2037.
9. Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010; 59: 84-95.
10. Honda M, Hayashi K, Matsuda H, et al. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis. Clin Sci 2001; 101: 421-427.
11. Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 295-312.
12. Arima S, Kohagura K, Xu HL, et al. Nongenimic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
13. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
14. Imagawa K, Okayama S, Takaoka M, et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma(H295R) cells. J Cardiovasc Pharmacol 2006; 44; 133-138.
15. Akizuki O, Inayoshi A, Kitayama T, et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424-434.
16. Tanaka T, Tsutamoto T, Sakai H, et al. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 2007; 30: 691-697.
17. Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res. 2011; 34: 268-273.
18. Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drug Ther 1998, 12: 463-467.
19. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478.
20. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
21. Watanabe M, Hirano T, Okamoto S, et al. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study. Hypertens Res 2010; 33: 43-48.
22. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005; 28: 1017-1023.
23. Nagasu H, Satoh M, Fujimoto S, et al. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res 2012; 35: 348-355.
24. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
25. Hayashi K, Saruta T, Goto Y, et al. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res2010; 11: 1211-1220.
26. Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009; 24: 301-307.
27. Fujita T, Ando K, Nishimura H, et al. Cilnidipine versus amlodipine randomised trial for evaluation in renal disease (CARTER) study Investigators. Kidney Int 2007; 72: 1543-1549.
28. Astor BC, Yi S, Hiremath L, et al. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation 2008; 117: 1685-1692.
29. Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study. Hypertension Research 2009; 32: 505-512.